Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GM-CSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas

Journal of Neuro-Oncology

Volumn 85, Issue 3, 2007, Pages 231-240

  Mariani, Christopher L ^a,b   Rajon, Didier ^a   Bova, Francis J ^a   Streit, Wolfgang J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Brain tumor; Denditic cells; Glioblastoma multiforme; Macrophages; Radiation therapy; Rat; Toll like receptor

Indexed keywords

CYTOTOXIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOPOLYSACCHARIDE; SODIUM CHLORIDE; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOMA; GROWTH INHIBITION; MALE; NONHUMAN; RADIATION DOSE; RAT; T LYMPHOCYTE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INJECTIONS, SUBCUTANEOUS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; RATS, NUDE; SUBCUTANEOUS TISSUE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ZYMOSAN;

EID: 36348942901     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9415-2     Document Type: Article

References (51)

1. Akman F, Cooper RA, Sen M, Tanriver Y, Kentli S (2002) Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: How useful are prognostic indices in routine clinical practice? J Neurooncol 59:39-47
2. Basso U, Ermani M, Vastola F, Brandes AA (2002) Non-cytotoxic therapies for malignant gliomas. J Neurooncol 58:57-69
3. Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26:397-409
4. Badie B, Schartner JM (2000) Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46:957-961; discussion 961-952
5. Graeber MB, Scheithauer BW, Kreutzberg GW (2002) Microglia in brain tumors. Glia 40:252-259
6. Kielian T, van Rooijen N, Hickey WF (2002) MCP-1 expression in CNS-1 astrocytoma cells: Implications for macrophage infiltration into tumors in vivo. J Neurooncol 56:1-12
7. Morioka T, Baba T, Black KL, Streit WJ (1992) Immunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma. Acta Neuropathol 83:590-597
8. Rossi ML, Hughes JT, Esiri MM, Coakham HB, Brownell DB (1987) Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol (Berl) 74:269-277
9. Huettner C, Paulus W, Roggendorf W (1995) Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 146:317-322
10. Merlo A, Juretic A, Zuber M, Filgueira L, Luscher U, Caetano V, Ulrich J, Gratzl O, Heberer M, Spagnoli GC (1993) Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns. Eur J Cancer 29A:2118-2125
11. Parney IF, Hao C, Petruk KC (2000) Glioma immunology and immunotherapy. Neurosurgery 46:778-791; discussion 791-772
12. Schneider J, Hofman FM, Apuzzo ML, Hinton DR (1992) Cytokines and immunoregulatory molecules in malignant glial neoplasms. J Neurosurg 77:265-273
13. Weller M, Fontana A (1995) The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 21:128-151
14. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M (2002) Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62:2592-2599
15. Giulian D, Baker TJ, Shih LC, Lachman LB (1986) Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med 164:594-604
16. Sawada M, Kondo N, Suzumura A, Marunouchi T (1989) Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 491:394-397
17. Dobrovolskaia MA, Vogel SN (2002) Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 4:903-914
18. Williams MA, Kelsey SM, Newland AC (1999) GM-CSF and stimulation of monocyte/macrophage function in vivo relevance and in vitro observations. Eur J Cancer 35(Suppl 3):S18-S22
19. Young SH, Ye J, Frazer DG, Shi X, Castranova V (2001) Molecular mechanism of tumor necrosis factor-alpha production in 1→-beta-glucan (zymosan)-activated macrophages. J Biol Chem 276:20781-20787
20. Miura T, Ohno N, Miura NN, Adachi Y, Shimada S, Yadomae T (1999) Antigen-specific response of murine immune system toward a yeast beta-glucan preparation, zymosan. FEMS Immunol Med Microbiol 24:131-139
21. Murata J, Ricciardi-Castagnoli P, Dessous L'Eglise Mange P, Martin F, Juillerat-Jeanneret L (1997) Microglial cells induce cytotoxic effects toward colon carcinoma cells: Measurement of tumor cytotoxicity with a gamma-glutamyl transpeptidase assay. Int J Cancer 70:169-174
22. Beutler B, Rietschel ET (2003) Innate immune sensing and its roots: The story of endotoxin. Nat Rev Immunol 3:169-176
23. Berendt MJ, North RJ, Kirstein DP (1978) The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med 148:1550-1559
24. Goto S, Sakai S, Kera J, Suma Y, Soma GI, Takeuchi S (1996) Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 42:255-261
25. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R, Engelhardt R (1996) Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 32A:1712-1718
26. Shear MJ, Turner FC (1943) Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 4:81-97
27. Engelhardt R, Mackensen A, Galanos C, Andreesen R (1990) Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 9:480-491
28. Chicoine MR, Won EK, Zahner MC (2001) Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. Neurosurgery 48:607-614; discussion 614-605
29. Won EK, Zahner MC, Grant EA, Gore P, Chicoine MR (2003) Analysis of the antitumoral mechanisms of lipopolysaccharide against glioblastoma multiforme. Anticancer Drugs 14:457-466
30. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499-511
31. Pistoia V (1991) Granulocyte-macrophage colony stimulating factor (GM-CSF); sources, targets and mechanism of action. Leukemia 5(Suppl 1):114-118
32. Wallenfriedman MA, Conrad JA, DelaBarre L, Graupman PC, Lee G, Garwood M, Gregerson DS, Jean WC, Hall WA, Low WC (1999) Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg 90:1064-1071
33. Dranoff G (2002) GM-CSF-based cancer vaccines. Immunol Rev 188:147-154
34. Dranoff G (2003) GM-CSF-secreting melanoma vaccines. Oncogene 22:3188-3192
35. Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, Waldhoer T, Oberhuber G, Ferenci P, Gangl A, Mueller C (2002) Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J Immunother 25:489-499
36. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G (2003) Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21:624-630
37. Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC (2003) Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer 88:1346-1351
38. Barth RF (1998) Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36:91-102
39. Hoeller C, Jansen B, Heere-Ress E, Pustelnik T, Mossbacher U, Schlagbauer-Wadl H, Wolff K, Pehamberger H (2001) Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J Invest Dermatol 117:371-374
40. +T cell-mediated suppression by dendritic cells. Science 299:1033-1036
41. Matzinger P (2002) The danger model: A renewed sense of self. Science 296:301-305
42. Zeisberger E, Roth J (1998) Tolerance to pyrogens. Ann N Y Acad Sci 856:116-131
43. Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5:508-515
44. Jiang H, Stewart CA, Fast DJ, Leu RW (1992) Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target. J Immunol 149:2137-2146
45. Berendt MJ, North RJ (1980) T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69-80
46. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L (2005) Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 11:361-369
47. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64:5074-5077
48. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5:397-405
49. + T cells compared. J Immunol 154:4309-4321
50. Carpentier AF, Xie J, Mokhtari K, Delattre JY (2000) Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6:2469-2473
51. Bowles AP Jr, Perkins E (1999) Long-term remission of malignant brain tumors after intracranial infection: A report of four cases. Neurosurgery 44:636-642; discussion 642-633